News
avril 2026
-
22 April 2026The Merck “3 Baskets” approach, Future Market Insights report on the OOC market, Anivance AI selected by the FNIH NAMs pilot, OpenAI Foundation for Alzheimer, and more
NEWS, REPORTS & POSITION STATEMENTS 1. The Merck “3 Baskets” approach for creating roadmaps to phase out animal testing In ALTEX latest issue, Kerstin Kleinschmidt-Doerr et al. describe their Merck KGaA 3 Baskets (3B) strategy, introduced in 2021, to reduce […]
Read more -
16 April 2026ICH S7A revised after 25 Years, Harmonized definition for NAMs, OOC into space, Personalized models of Schizophrenia, and more
NEWS, REPORTS & POSITION STATEMENTS 1. ICH S7A revised after 25 Years: Why it matters for NAMs developers The International Council for Harmonisation (ICH) S7A guideline on safety pharmacology studies, finalized in 2000, has been pivotal in protecting clinical trial […]
Read more -
8 April 2026Standardizing NAMs, 2025 ECVAM Status Report, Anthropic’s life sciences strategy, Non-clinical safety assessment of vaccines, and more
NEWS, REPORTS & POSITION STATEMENTS 1. Novo Nordisk principal scientist highlights the urgency of advancing human-relevant 3D tissue models As regulatory momentum accelerates globally to reduce reliance on animal testing, leading experts in microphysiological systems (MPS), complex in vitro models […]
Read more -
1 April 2026UK regulatory guidance for NAMs, Nature collection on organoid models for infectious diseases, AI agents in drug discovery and more
NEWS, REPORTS & POSITION STATEMENTS 1. UK: MHRA published guidance on its approach to medicines developed using non-animal methods The Medicines and Healthcare products Regulatory Agency (MHRA) is the regulator of medicines, medical devices and blood components for transfusion in […]
Read more
